Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
12 p, 600.5 KB A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma / Carlo-Stella, Carmelo (Humanitas Research Hospital (Itàlia)) ; Zinzani, Pier Luigi (IRCCS Azienda Ospedaliero-Universitaria di Bologna) ; Sureda, Anna (Hospital Universitari de Bellvitge) ; Araújo, Luis (Universitário de Coimbra) ; Casasnovas, Olivier (CHU Dijon Bourgogne) ; Carpio Segura, Cecilia del Carmen (Hospital Universitari Vall d'Hebron) ; Yeh, Su-Peng (China Medical University Hospital) ; Bouabdallah, Krimo (University Hospital of Bordeaux) ; Cartron, Guillaume (Centre Hospitalier Universitaire Montpellier) ; Kim, Won Seog (Samsung Medical Center) ; Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz) ; Koh, Youngil (Seoul National University Hospital) ; Re, Alessandro (ASST Spedali Civili Brescia) ; Alves, Daniela (Centro Hospitalar Universitário Lisboa Norte) ; Chamuleau, Martine (Vrije Universiteit Amsterdam) ; Le Gouill, Steven (Institut Curie) ; López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ; Moreira, Ilídia (Portuguese Institute of Oncology of Porto) ; van der Poel, Marjolein W. M. (Maastricht University Medical Center) ; Abbadessa, Giovanni (Sanofi) ; Meng, Robin (Sanofi) ; Ji, Ran (Sanofi) ; Lépine, Lucie (Sanofi) ; Saleem, Rao (Sanofi) ; Ribrag, Vincent (Institut Gustave Roussy (Villejuif, França)) ; Universitat Autònoma de Barcelona
Patients with relapsed or refractory lymphoma have limited treatment options, requiring newer regimens. In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in combination with cemiplimab (Cemi, anti-programmed death-1 [PD-1] receptor antibody; Isa + Cemi) in patients with classic Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma (PTCL). [...]
2022 - 10.1002/hon.3089
Hematological Oncology, Vol. 41 (october 2022) , p. 108-119  
2.
11 p, 1.4 MB Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma / Timmerman, John (UCLA Medical Center) ; Herbaux, Charles (Centre Hospitalier Régional Universitaire de Lille) ; Ribrag, Vincent (Institut Gustave Roussy (Villejuif, França)) ; Zelenetz, Andrew D. (Memorial Sloan Kettering Cancer Center) ; Houot, Roch (Unité dʼInvestigation Clinique) ; Neelapu, Sattva S. (The University of Texas MD Anderson Cancer Center) ; Logan, Theodore (Indiana University) ; Lossos, Izidore S. (Sylvester Comprehensive Cancer Center) ; Urba, Walter (Providence Cancer Center) ; Salles, Gilles (Université de Lyon) ; Ramchandren, Radhakrishnan (Karmanos Cancer Institute) ; Jacobson, Caron (Harvard Medical School) ; Godwin, John (Providence Cancer Center) ; Carpio Segura, Cecilia del Carmen (Universitat Autònoma de Barcelona. Departament de Medicina) ; Lathers, Deanne (Bristol-Myers Squibb) ; Liu, Yali (Bristol-Myers Squibb) ; Neely, Jaclyn (Bristol-Myers Squibb) ; Suryawanshi, Satyendra (Bristol-Myers Squibb) ; Koguchi, Yoshinobu (Providence Cancer Center) ; Levy, Ronald (Stanford University School of Medicine)
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. [...]
2020 - 10.1002/ajh.25757
American Journal of Hematology, Vol. 95 (february 2020) , p. 510-520  

Vea también: autores con nombres similares
1 Ribrag, V.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.